Background: In both human subjects and mice, T helper cells are classified into 2 subsets, TH1 and TH2 cells, on the basis of the cytokines they produce. Although IFN-alpha has been shown to enhance human TH1 responses, its influences on human TH2 responses have not yet been fully characterized. In addition, the mechanism for induction of TH1 responses by IFN-alpha has not been fully delineated.
Objective: The present study was undertaken to explore the direct effects of IFN-alpha on the expression of various cytokines in human CD4+ T cells with a system using immobilized anti-CD3, which permits activation of CD4+ T cells in the complete absence of accessory cells.
Methods: Highly purified CD4+ T cells obtained from healthy donors were stimulated with immobilized anti-CD3 with or without IFN-alpha and IL-12 in the complete absence of accessory cells. The production of cytokines was estimated by means of ELISA. The expression of mRNA for various cytokines, as well as transcription factors, was evaluated by using quantitative PCR.
Results: IFN-alpha enhanced IL-4 protein and mRNA expression in immobilized anti-CD3-stimulated CD4+ T cells, irrespective of the presence of IL-12, whereas IFN-alpha suppressed the expression of IL-5 and IL-13. Of note, IFN-alpha enhanced the expression of mRNA for c-Maf, T-bet, and Fox-P3, irrespective of the presence of IL-12, but not that for GATA-3, in anti-CD3-stimulated CD4+ T cells.
Conclusion: These results indicate that IFN-alpha enhances the induction of TH1 responses through upregulation of T-bet mRNA expression, as well as the induction of TH2 responses through upregulation of c-Maf mRNA expression, followed by IL-4 expression. Moreover, the data also suggest that IFN-alpha might suppress the expression of IL-5 and IL-13 in differentiated TH2 cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2005.03.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab Leads to Complete Response in an HIV Patient With a Solid Tumor and a Cluster of Differentiation 4 (CD4) Count Less Than 100.
Cureus
December 2024
Hematology/Oncology, University of Kansas Medical Center, Kansas City, USA.
A 58-year-old male, with a history of human immunodeficiency virus (HIV) and stage 4 left frontotemporal squamous cell carcinoma (SCC), presented with new-onset neck pain. He was diagnosed with HIV five years prior. The patient had a cluster of differentiation 4 (CD4) count of 53 cells/mm³ and a high viral load, later suppressed with bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy).
View Article and Find Full Text PDFImmune deficits after CD19 chimeric antigen receptor (CAR) T-cell therapy can be long-lasting, predisposing patients to infections and non-relapse mortality. In B-cell non-Hodgkin lymphoma (B-NHL), the prognostic impact of immune reconstitution (IR) remains ill-defined, and detailed cross-product comparisons have not been performed to date. In this retrospective observational study, we longitudinally characterized lymphocyte subsets and immunoglobulin levels in 105 B-NHL patients to assess patterns of immune recovery arising after CD19 CAR-T.
View Article and Find Full Text PDFRevisiting the classical target cell limited dynamical within-host HIV model - Basic mathematical properties and stability analysis.
Math Biosci Eng
December 2024
Department of Engineering and Natural Sciences, University of Applied Sciences Merseburg, Eberhard-Leibnitz-Str. 2, D-06217 Merseburg, Germany.
In this article, we reconsider the classical target cell limited dynamical within-host HIV model, solely taking into account the interaction between $ {\rm{CD}}4^{+} $ T cells and virus particles. First, we summarize some analytical results regarding the corresponding dynamical system. For that purpose, we proved some analytical results regarding the system of differential equations as our first main contribution.
View Article and Find Full Text PDFThe differences in the distribution characteristics and prognostic value of tumor-infiltrating T lymphocyte subsets between lung adenocarcinoma and lung squamous cell carcinoma.
Chin Clin Oncol
December 2024
Department of Oncology Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: The characteristics of tumor immune microenvironment are important factors affecting the efficacy of immunotherapy, and there are differences in the distribution of tumor-infiltrating lymphocyte (TIL) subsets in different types of tumors. This study aims to compare the distributions of cluster of differentiation (CD) 4+ and CD4+ T cell subsets of TILs and their clinical significance between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).
Methods: The tumor tissues of 78 LUAD and 56 LUSC patients who underwent surgery at The Second Affiliated Hospital of Zhengzhou University between October 2020 and October 2022 were collected, TIL level were detected by pathological observation, and the proportions of CD4+, CD4+ T cell subsets and CD4+/CD4+ ratio in TILs were detected by flow cytometry.
EFFICACY AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE IN ANTIRETROVIRAL THERAPY-NAIVE PEOPLE LIVING WITH HIV-1 AND WITH HIGH-LEVEL VIREMIA.
J Acquir Immune Defic Syndr
January 2025
Department of Medical and Surgical Sciences, Unit of Infectious Diseases, S.Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: Dual regimen dolutegravir/lamivudine (DOL/3TC) showed potent efficacy and favourable safety in both antiretroviral therapy-naïve and -experienced patients, but data from real life about naive people with high-level viremia are still lacking.
Methods: We performed a retrospective cohort study of people living with HIV (PLWH) who were naive to antiretroviral therapy, had baseline HIV-1 RNA ranging from 100000 to 500000 copies/mL, and initated DOL/3TC. Virological efficacy and changes in immunological parameters after 12 months of treatment were evaluated and compared with highly viremic PLWH who started a triple antiretroviral combination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!